Mubashir Qazi, MD
Interventional Cardiology · Lexington, KYNPI 1568437366
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $13,443 of the $17,630 with a category attached, or 76.3%. It is spread thinly across 51 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $6,236 and has fallen 55.7% since, to $2,762 in 2025.
Across 855 payments — averaging $20.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$4K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
- Johnson & Johnson$2K
- Novartis$2K
- Amgen$1K
- AstraZeneca$871
- plus $7K from 45 others
Across 266 payments — averaging $289.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$77K
What the payments were for
- Speaking & faculty fees$4,12523%
- Food & beverage$13,44376%
- Education$610%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$2,732
- Rapiblyk$1,675
- LifeVest$1,607
- OPTIMIZER$217
- ATRICLIP LAA EXCLUSION SYSTEM$159
- Pulmonx Endobronchial Valve EBV$128
- WAINUA$122
- Confirm Rx$121
- VYNDAQEL$101
How this compares
$17,630 in reported general payments places this provider in the 70th percentile of 129 interventional cardiology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 811 | $989,759 |
| EntrestoSacubitril/Valsartan | 427 | $588,834 |
| JardianceEmpagliflozin | 374 | $459,407 |
| XareltoRivaroxaban | 277 | $326,450 |
| BrilintaTicagrelor | 185 | $163,064 |
| Repatha SureclickEvolocumab | 148 | $133,458 |
| FarxigaDapagliflozin Propanediol | 96 | $93,107 |
| NexlizetBempedoic Acid/Ezetimibe | 83 | $68,931 |
| OzempicSemaglutide | 30 | $50,608 |
| VascepaIcosapent Ethyl | 78 | $49,859 |
| Praluent PenAlirocumab | 42 | $34,971 |
| MultaqDronedarone Hcl | 23 | $30,825 |
| Ranolazine ErRanolazine | 246 | $27,039 |
| KerendiaFinerenone | 17 | $20,039 |
| Repatha SyringeEvolocumab | 21 | $17,960 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $3,653 | $989,759811 claims |
| NovartisEntresto | $1,598 | $588,834427 claims |
| Boehringer IngelheimJardiance | $171 | $459,407374 claims |
| Johnson & JohnsonXarelto | $1,787 | $326,450277 claims |
| AstraZenecaBrilinta, Farxiga | $871 | $256,171281 claims |
| Esperion Therapeutics, Inc.Nexlizet | $462 | $68,93183 claims |
| Novo NordiskOzempic | $767 | $50,60830 claims |
| Sanofi-aventis U.S. LLCMultaq | $556 | $30,82523 claims |
| BayerKerendia | $304 | $20,03917 claims |
| Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor | $37 | $17,34630 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 129 interventional cardiology providers in Kentucky.
Other interventional cardiology in Lexington
- Avichai EresLexington$616K
- Steve LinLexington$362K
- Robert SawyerLexington$249K
- Ganesh Keshav ThirunavukkarasuLexington$220K
- Armaghan SoomroLexington$117K
- Adrian MesserliLexington$41K
- Hussam HamdallaLexington$24K
- Henry Charles RichmondLexington$20K
- Michael ShihLexington$20K
- Michael RukavinaLexington$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.